Utilized for stroke prevention and DVT to manage blood clotting and support cardiovascular safety.
Mechanism of Action
Apixaban is a highly selective inhibitor of Factor Xa. By blocking this central protease in the coagulation cascade, it prevents the generation of thrombin and the formation of fibrin clots without requiring routine INR monitoring.
Route of Administration
Oral
Onset Time
3–4 hours
Duration
12 hours (half-life)
Contraindications
Active pathological bleeding, Severe hepatic impairment, Hypersensitivity to apixaban
Severe Adverse Events
Major hemorrhage, Spinal hematoma, Anaphylaxis — requires immediate medical attention
Information related to Eliquis is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
